Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H11NO2 |
| Molecular Weight | 165.1891 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=CC=C(N)C=C1
InChI
InChIKey=BLFLLBZGZJTVJG-UHFFFAOYSA-N
InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
| Molecular Formula | C9H11NO2 |
| Molecular Weight | 165.1891 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.fda.gov/drugs/drugsafety/ucm250024.htm
Curator's Comment: description was created based on several sources, including
https://www.fda.gov/drugs/drugsafety/ucm250024.htm
Benzocaine is a local anesthetic. It acts by blocking voltage-gated sodium ion channels in nerve endings. Benzocaine is available over-the counter for local anesthesia of oral and pharyngeal mucous membranes (sore throat, cold sores, mouth ulcers, toothache, sore gums, denture irritation), otic pain, and as a local anesthetic for surgical or diagnostic procedures. As a spray, benzocaine is used for temporary relief of pain and itching associated with minor burns, sunburn, minor cuts or scrapes, insect bites, or minor skin irritations. Topical application of benzocaine to gums or mouth may cause rare, but serious and potentially fatal adverse effect methemoglobinemia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9Y5Y9 Gene ID: 6336.0 Gene Symbol: SCN10A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19661462 |
0.32 mM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | CEPACOL Approved UseBenzocaine lozenges are used to relieve pain and irritation caused by sore throat, sore mouth, or canker sores. |
|||
| Palliative | CEPACOL Approved UseBenzocaine lozenges are used to relieve pain and irritation caused by sore throat, sore mouth, or canker sores. |
|||
| Palliative | CEPACOL Approved UseBenzocaine lozenges are used to relieve pain and irritation caused by sore throat, sore mouth, or canker sores. |
|||
| Palliative | AMERICAINE Approved UseSelf-medication for temporary relief of pain and itching associated with minor burns, sunburn, minor cuts or scrapes, insect bites, or minor skin irritations. |
|||
| Palliative | AMERICAINE HEMORRHOIDAL Approved UseSelf-medication for temporary relief of pain and itching associated with hemorrhoids |
|||
| Palliative | OTOCAINE DROPS Approved UseRelieving pain and itching in the ear caused by ear infections. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 % single, topical Dose: 20 % Route: topical Route: single Dose: 20 % Sources: |
unhealthy, 17-71 years Health Status: unhealthy Age Group: 17-71 years Sex: F Sources: |
Other AEs: Methaemoglobinaemia... Other AEs: Methaemoglobinaemia (2 patients) Sources: |
8 mg 1 times / 2 hours multiple, oral Dose: 8 mg, 1 times / 2 hours Route: oral Route: multiple Dose: 8 mg, 1 times / 2 hours Sources: |
unhealthy, 49.4 years (range: 18–74 years) Health Status: unhealthy Age Group: 49.4 years (range: 18–74 years) Sex: M+F Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Methaemoglobinaemia | 2 patients | 20 % single, topical Dose: 20 % Route: topical Route: single Dose: 20 % Sources: |
unhealthy, 17-71 years Health Status: unhealthy Age Group: 17-71 years Sex: F Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19661462/ Page: - |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25010377/ Page: - |
yes | |||
Sources: https://dmd.aspetjournals.org/content/47/3/271 Page: - |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute methemoglobinemia after endoscopy. | 2004-07-01 |
|
| Prospective randomized study of viscous lidocaine versus benzocaine in a GI cocktail for dyspepsia. | 2004-07 |
|
| Reported adverse event cases of methemoglobinemia associated with benzocaine products. | 2004-06-14 |
|
| George Crile, Harvey Cushing, and the Ambulance Americaine: military medical preparedness in World War I. | 2004-06 |
|
| A high prevalence of sensitization still persists in leg ulcer patients: a retrospective series of 106 patients tested between 2001 and 2002 and a meta-analysis of 1975-2003 data. | 2004-05 |
|
| Iatrogenic methemoglobinemia from benzocaine spray in trauma. | 2004-05 |
|
| Contact dermatitis and other skin conditions in instrumental musicians. | 2004-04-16 |
|
| Effects of the local anesthetic benzocaine on the human erythrocyte membrane and molecular models. | 2004-04-01 |
|
| Respiratory failure secondary to methemoglobinemia induced by benzocaine: a case report. | 2004-04 |
|
| Critical rebound methemoglobinemia after methylene blue treatment: case report. | 2004-04 |
|
| Tongue entrapment in an aluminum juice can. | 2004-04 |
|
| The need for caution with topical anesthesia during endoscopic procedures, as liberal use may result in methemoglobinemia. | 2004-03 |
|
| Methemoglobinemia: an unusual cause of postoperative cyanosis. | 2004-03 |
|
| Can clinical trials requiring frequent participant contact be conducted over the Internet? Results from an online randomized controlled trial evaluating a topical ointment for herpes labialis. | 2004-02-17 |
|
| Detection of apple juice concentrate in the manufacture of natural and sparkling cider by means of HPLC chemometric sugar analyses. | 2004-01-28 |
|
| Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N(4)]-chloride platinum (II) monohydrochloride monohydrate. | 2004-01 |
|
| Colorimetric determination of benzocaine, lignocaine and procaine hydrochlorides in pure form and in pharmaceutical formulations using p-benzoquinone. | 2003-10 |
|
| Analgesic synergy between topical morphine and butamben in mice. | 2003-10 |
|
| Children's preference of benzocaine gel versus the lidocaine patch. | 2003-09-19 |
|
| Angioedema as a complication of upper endoscopy. | 2003-08-05 |
|
| Lipid-protein interactions and effect of local anesthetics in acetylcholine receptor-rich membranes from Torpedo marmorata electric organ. | 2003-08-05 |
|
| The association between ambient air conditions (temperature and absolute humidity), irritant sodium lauryl sulfate patch test reactions and patch test reactivity to standard allergens. | 2003-08 |
|
| Dangerous in small amounts: ten nondrug substances that cause harm. | 2003-08 |
|
| Preparation and evaluation of bioadhesive benzocaine gels for enhanced local anesthetic effects. | 2003-07-09 |
|
| Bye-bye benzocaine? | 2003-07 |
|
| Influence of site preparation methods on the pain reported during palatal infiltration using the Wand Local Anesthetic System. | 2003-06 |
|
| Effects of isoeugenol on in vitro neuromuscular blockade of rat phrenic nerve-diaphragm preparations. | 2003-06 |
|
| Severe methemoglobinemia after transesophageal echocardiography. | 2003-05-21 |
|
| Suspected methemoglobinemia following awake intubation: one possible effect of benzocaine topical anesthesia--a case report. | 2003-04 |
|
| Spectrophotometric determination of labetalol in pharmaceutical preparations and spiked human urine. | 2003-04 |
|
| Two cases of methemoglobinemia from the use of topical anesthetics. | 2003-04 |
|
| Benzocaine-induced methemoglobinemia. | 2003-03 |
|
| Thermodynamics of partitioning of benzocaine in some organic solvent/buffer and liposome systems. | 2003-03 |
|
| Effect of prolonged exposure to low antigen concentration for sensitization. | 2003-02-14 |
|
| Evolution of sugars in cider brandy aged in oak barrels: a contribution to its characterization. | 2003-02-12 |
|
| Patch testing with the irritant sodium lauryl sulfate (SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. | 2003-02 |
|
| Black henna tattoo reaction in a person with sulfonamide and benzocaine drug allergies. | 2003-02 |
|
| Benzocaine-induced methemoglobinemia: experience from a high-volume transesophageal echocardiography laboratory. | 2003-02 |
|
| Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain. | 2003-02 |
|
| Anesthesia of fish with benzocaine does not interfere with comet assay results. | 2003-01-10 |
|
| Methemoglobinemia and topical pharyngeal anesthesia. | 2003-01-02 |
|
| Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. | 2003-01 |
|
| Effectiveness of 20% benzocaine as a topical anesthetic for intraoral injections. | 2003 |
|
| Benzocaine-induced methemoglobinemia: a potentially fatal complication of transesophageal echocardiography. | 2003 |
|
| Efficacy and tolerability of an intraoral benzocaine patch in the relief of spontaneous toothache pain. | 2003 |
|
| Determination of linkages of linear and branched oligosaccharides using closed-ring chromophore labeling and negative ion trap mass spectrometry. | 2002-11 |
|
| The use of lubricants to achieve tracheal intubation in neonates and infants. | 2002-10 |
|
| [Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)]. | 2002-10 |
|
| Should a mucoadhesive patch (DentiPatch) be used for gingival anesthesia in children? | 2002 |
|
| Evaluation of an acetic acid ester of monoglyceride as a suppository base with unique properties. | 2001-07-17 |
Sample Use Guides
Apply topically to the skin as an aerosol spray, cream, lotion, ointment, or solution.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19661462
Benzocaine produced voltage-sensor inhibition in voltage-gated Na+ channel (Nav1.5) expressed in HEK293 cells, and caused large leftward shifts in the V1/2 of the steady-state availability curves aswell as a reduction in Imax with an ED50 of 0.32 mM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 18:52:36 GMT 2025
by
admin
on
Wed Apr 02 18:52:36 GMT 2025
|
| Record UNII |
U3RSY48JW5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 346.10
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
CFR |
21 CFR 310.531
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
EPA PESTICIDE CODE |
97001
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-VATC |
QN01AX92
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-ATC |
D04AB04
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-VATC |
QN01BA05
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-ATC |
R02AD01
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
CFR |
21 CFR 348.10
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-ATC |
C05AD03
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
CFR |
21 CFR 310.538
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-ATC |
N01BA05
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-VATC |
QR02AD01
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-VATC |
QC05AD03
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
WHO-VATC |
QD04AB04
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D001566
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
100000089829
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
U3RSY48JW5
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
N0000171131
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
N0000184306
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
116735
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL278172
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
m2358
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
202-303-5
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
1399
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
94-09-7
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
C28923
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
BENZOCAINE
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Very slightly soluble in water; soluble in 6 parts of ethanol (~750 g/l) TS and 5.5 parts of ether R. Category: Local anaesthetic. Storage: Benzocaine should be kept in a well-closed container, protected from light. Additional information: Benzocaine causes local numbness after being placed on the tongue. Definition: Benzocaine contains not less than 98.0% and not more than 101.0% of C9H11NO2, calculated with reference to the dried substance. | ||
|
DTXSID8021804
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
323
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
4688
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
1054000
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
41531
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
BENZOCAINE
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
3953
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
2337
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
7225
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
Benzocaine
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
DB01086
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
U3RSY48JW5
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY | |||
|
SUB05755MIG
Created by
admin on Wed Apr 02 18:52:36 GMT 2025 , Edited by admin on Wed Apr 02 18:52:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.48.pdf
|